Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pegasys

Roche Basel Switzerland

Roche acquires cancer biobank firm Signature Diagnostics

Marks Swiss firm's fifth deal this year to expand its molecular diagnostics business

- PMLiVE

ViiV maintains top spot in reputation survey

But former top-ranked Gilead slides down in PatientView poll of patient groups

Gilead Sciences

Gilead and Achillion see 100% success rate in hep C trial

New combination treatment aims to compete in a rapidly evolving market for the disease

- PMLiVE

Non-profit calls to revoke Sovaldi’s European patent

Doctors of the World says Gilead is “abusing its patent” to impose unsustainable prices

Roche Basel Switzerland

Fresh approval for Roche’s Lucentis as competition heats up

Approved for more diabetes-related eye complications

- PMLiVE

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

Roche - Basel

Roche’s PD-1 wins second FDA ‘breakthrough’ status

Will accelerate review of MPDL3280A in lung cancer

Roche Basel Switzerland

Roche’s newer breast cancer drugs gain traction

Perjeta and Kadcyla boost 2014 revenues

- PMLiVE

Former Roche CEO joins BIAL board

Franz Humer to advise Portuguese pharma company

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

Gilead Sciences

Gilead cuts hepatitis C drug prices in Germany

Discount on Sovaldi and Harvoni follows similar agreement in France

- PMLiVE

Indian generics firm GVK set to be hit with European sales ban

EU regulator raises concerns on conduct of drug studies in India

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links